Thus, AID promotes mutagenesis in CLL cells under BCR inhibition, suggesting that the mutagenic activity of AID does not contribute to the emergence of resistance to BCR pathway inhibitors and that resistance likely arises through adaptation rather than mutations in other driver oncogenes. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.